Join Growin Stock Community!

醣基6586.TW Overview

TW StockBiotech. & Medical
(No presentation for 6586)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

醣基（6586）Overall Performance

醣基（6586）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

醣基（6586） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

醣基（6586）Key Information

醣基（6586）Profile

CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which is in Phase I/IIa clinical trials for the treatment of refractory non-Hodgkin lymphoma; CHO-A04, a humanized monoclonal antibody, which is in phase I clinical trials to treat various tumor and cancer stem cells; and CHO-V08 vaccines for the treatment of klebsiella pneumonia. Further, it develops CHO-H02 that is in preclinical stage to target solid tumors, including breast, bladder, pancreatic, ovarian, and gastric cancers; and CHO-H03, an antibody drug that is in pre-clinical development stage indicated for inflammatory conditions in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in Taipei City, Taiwan.

醣基（6586）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.27
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1271.50
PB Ratio
2.07
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
51.54%
Net Margin
-11314.75%
Revenue Growth (YoY)
18.24%
Profit Growth (YoY)
-35.28%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.27
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1271.50
PB Ratio
2.07
Price-to-FCF
-
Gross Margin
51.54%
Net Margin
-11314.75%
Revenue Growth (YoY)
18.24%
Profit Growth (YoY)
-35.28%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
default symbol

6586

醣基

25.50D

-2.94%

(-0.03)

  • When is 6586's latest earnings report released?

    The most recent financial report for 醣基 (6586) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6586's short-term business performance and financial health. For the latest updates on 6586's earnings releases, visit this page regularly.

  • What is the operating profit of 6586?

    According to the latest financial report, 醣基 (6586) reported an Operating Profit of -136.73M with an Operating Margin of -19,203.09% this period, representing a decline of 15.81% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 6586's revenue growth?

    In the latest financial report, 醣基 (6586) announced revenue of 712K, with a Year-Over-Year growth rate of -34.2%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 6586 have?

    At the end of the period, 醣基 (6586) held Total Cash and Cash Equivalents of 168.87M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6586 go with three margins increasing?

    In the latest report, 醣基 (6586) did not achieve the “three margins increasing” benchmark, with a gross margin of 70.51%%, operating margin of -19,203.09%%, and net margin of -16,590.73%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6586's profit trajectory and future growth potential.

  • Is 6586's EPS continuing to grow?

    According to the past four quarterly reports, 醣基 (6586)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.55. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 6586?

    醣基 (6586)'s Free Cash Flow (FCF) for the period is 11.35M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 37.18% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.